Saudi Arabia ai genomics market report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
Description
Saudi Arabia AI Genomics Market Overview
The Saudi Arabia AI Genomics Market is valued at USD 9 million, based on a five-year historical analysis. This growth is primarily driven by advancements in artificial intelligence technologies, increasing investments in genomics research, and a rising demand for personalized medicine. The integration of AI in genomics has enhanced data analysis capabilities, leading to improved healthcare outcomes and innovative drug development processes. Recent market trends highlight the rapid adoption of next-generation sequencing platforms, expanding clinical diagnostics, and strategic public-private partnerships, especially under the Vision 2030 healthcare transformation initiative, which is accelerating technology transfer and infrastructure development .
Key players in this market include
Riyadh, Jeddah, and Dammam
, which dominate due to their robust healthcare infrastructure, presence of leading research institutions, and government support for genomics initiatives. These cities are also home to major hospitals and biotechnology firms that are pivotal in driving innovation and collaboration in the AI genomics sector .
In 2023, the Saudi government launched the
National Strategy for Data and Artificial Intelligence
(NSDAI), issued by the Saudi Data and Artificial Intelligence Authority (SDAIA). This initiative includes a dedicated focus on genomics, aiming to enhance the country's capabilities in AI and genomics through investments in research and development, fostering partnerships between public and private sectors, and promoting the use of AI technologies in healthcare. The NSDAI mandates operational standards for data governance, privacy, and interoperability in healthcare AI applications, including genomics .
Saudi Arabia AI Genomics Market Segmentation
By Type:
The segmentation of the market by type includes various genomic technologies that cater to different research and clinical needs. The subsegments are Whole Genome Sequencing, Exome Sequencing, Targeted Sequencing, RNA Sequencing, Next-Generation Sequencing (NGS), PCR Amplification, Capillary Electrophoresis, and Others. Among these,
Next-Generation Sequencing (NGS)
is the most dominant due to its high throughput and cost-effectiveness, making it the preferred choice for large-scale genomic studies and clinical applications. The adoption of NGS is driven by its ability to deliver rapid, accurate, and scalable genomic data, which is crucial for precision medicine and drug discovery .
By End-User:
The market segmentation by end-user includes Hospitals, Research Institutions, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Government Genomics Initiatives (e.g., Saudi Human Genome Program), and Others.
Hospitals
are the leading end-user segment, driven by the increasing adoption of genomic testing for personalized medicine and disease management, which enhances patient care and treatment outcomes. The growing prevalence of genetic disorders and chronic diseases, coupled with government funding for genomics research, is further boosting demand among hospitals and research institutions .
Saudi Arabia AI Genomics Market Competitive Landscape
The Saudi Arabia AI Genomics Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., QIAGEN N.V., Roche Sequencing Solutions, Agilent Technologies, Inc., PerkinElmer, Inc., Eurofins Scientific SE, Genomatix Software GmbH, 10x Genomics, Inc., Oxford Nanopore Technologies Ltd., Bio-Rad Laboratories, Inc., Ginkgo Bioworks, Inc., Myriad Genetics, Inc., Invitae Corporation, Sophia Genetics SA, Deep Genomics Inc., Fa
ic Genomics, Inc., Data4Cure, Inc., Saudi Human Genome Program (King Abdulaziz City for Science and Technology - KACST), King Faisal Specialist Hospital & Research Centre (Genomics and Precision Medicine Unit), Saudi Data and Artificial Intelligence Authority (SDAIA) contribute to innovation, geographic expansion, and service delivery in this space.
Illumina, Inc.
1998
San Diego, California, USA
Thermo Fisher Scientific Inc.
2006
Waltham, Massachusetts, USA
BGI Genomics Co., Ltd.
1999
Shenzhen, China
QIAGEN N.V.
1986
Venlo, Netherlands
Roche Sequencing Solutions
2006
Basel, Switzerland
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
Revenue Growth Rate (Saudi Arabia AI Genomics Segment)
Market Penetration Rate (Saudi Arabia)
Number of AI-Genomics Deployments/Projects in Saudi Arabia
R&D Investment as % of Revenue
Local Partnerships/Collaborations (Count/Key Names)
Saudi Arabia AI Genomics Market Industry Analysis
Growth Drivers
Increasing Investment in Healthcare Technology:
Saudi Arabia's healthcare expenditure is projected to reach approximately SAR 250 billion (USD 66.7 billion) in future, driven by a commitment to enhance healthcare infrastructure. The government aims to allocate 6% of its GDP to healthcare, fostering advancements in AI genomics. This investment supports the integration of cutting-edge technologies, enabling improved patient outcomes and personalized treatment options, thereby propelling the AI genomics market forward.
Rising Prevalence of Genetic Disorders:
The prevalence of genetic disorders in Saudi Arabia is estimated at 1 in 3 births, with conditions such as thalassemia and sickle cell disease being particularly common. This alarming statistic underscores the urgent need for genomic solutions. The increasing number of diagnosed cases is driving demand for genomic testing and personalized medicine, creating a robust market for AI-driven genomic technologies that can provide targeted therapies and preventive measures.
Government Initiatives for Digital Health:
The Saudi government has launched the "Vision 2030" initiative, which emphasizes digital health transformation. By future, the government plans to implement over 150 digital health projects, including genomic data integration into healthcare systems. This initiative aims to enhance healthcare delivery and accessibility, fostering an environment conducive to the growth of AI genomics, as it aligns with national health priorities and technological advancements.
Market Challenges
High Costs of Genomic Sequencing:
The cost of genomic sequencing in Saudi Arabia can exceed SAR 40,000 (USD 10,700) per individual, which poses a significant barrier to widespread adoption. This high expense limits access to genomic testing, particularly for lower-income populations. As a result, many patients may not receive timely diagnoses or personalized treatments, hindering the overall growth of the AI genomics market in the region.
Limited Awareness Among Healthcare Providers:
A significant gap exists in the awareness and understanding of genomic technologies among healthcare providers in Saudi Arabia. Only about 40% of healthcare professionals are familiar with the applications of AI in genomics. This lack of knowledge can lead to underutilization of genomic services, limiting patient access to innovative treatments and impeding the market's potential growth in the healthcare sector.
Saudi Arabia AI Genomics Market Future Outlook
The future of the AI genomics market in Saudi Arabia appears promising, driven by ongoing advancements in technology and increasing healthcare investments. As the government continues to prioritize digital health initiatives, the integration of AI in genomic data analysis is expected to enhance precision medicine. Furthermore, the rising demand for personalized healthcare solutions will likely stimulate innovation, leading to the development of new diagnostic tools and therapies that cater to the unique genetic profiles of the population.
Market Opportunities
Expansion of Personalized Medicine:
The growing emphasis on personalized medicine presents a significant opportunity for the AI genomics market. With an increasing number of patients seeking tailored treatment options, the demand for genomic testing and analysis is expected to rise, enabling healthcare providers to offer more effective and individualized therapies that improve patient outcomes.
Collaborations with International Research Institutions:
Partnerships with global research institutions can enhance the capabilities of Saudi Arabia's AI genomics market. By leveraging international expertise and resources, local companies can accelerate the development of innovative genomic solutions, fostering knowledge exchange and driving advancements in research and technology that benefit the healthcare sector.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
The Saudi Arabia AI Genomics Market is valued at USD 9 million, based on a five-year historical analysis. This growth is primarily driven by advancements in artificial intelligence technologies, increasing investments in genomics research, and a rising demand for personalized medicine. The integration of AI in genomics has enhanced data analysis capabilities, leading to improved healthcare outcomes and innovative drug development processes. Recent market trends highlight the rapid adoption of next-generation sequencing platforms, expanding clinical diagnostics, and strategic public-private partnerships, especially under the Vision 2030 healthcare transformation initiative, which is accelerating technology transfer and infrastructure development .
Key players in this market include
Riyadh, Jeddah, and Dammam
, which dominate due to their robust healthcare infrastructure, presence of leading research institutions, and government support for genomics initiatives. These cities are also home to major hospitals and biotechnology firms that are pivotal in driving innovation and collaboration in the AI genomics sector .
In 2023, the Saudi government launched the
National Strategy for Data and Artificial Intelligence
(NSDAI), issued by the Saudi Data and Artificial Intelligence Authority (SDAIA). This initiative includes a dedicated focus on genomics, aiming to enhance the country's capabilities in AI and genomics through investments in research and development, fostering partnerships between public and private sectors, and promoting the use of AI technologies in healthcare. The NSDAI mandates operational standards for data governance, privacy, and interoperability in healthcare AI applications, including genomics .
Saudi Arabia AI Genomics Market Segmentation
By Type:
The segmentation of the market by type includes various genomic technologies that cater to different research and clinical needs. The subsegments are Whole Genome Sequencing, Exome Sequencing, Targeted Sequencing, RNA Sequencing, Next-Generation Sequencing (NGS), PCR Amplification, Capillary Electrophoresis, and Others. Among these,
Next-Generation Sequencing (NGS)
is the most dominant due to its high throughput and cost-effectiveness, making it the preferred choice for large-scale genomic studies and clinical applications. The adoption of NGS is driven by its ability to deliver rapid, accurate, and scalable genomic data, which is crucial for precision medicine and drug discovery .
By End-User:
The market segmentation by end-user includes Hospitals, Research Institutions, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Government Genomics Initiatives (e.g., Saudi Human Genome Program), and Others.
Hospitals
are the leading end-user segment, driven by the increasing adoption of genomic testing for personalized medicine and disease management, which enhances patient care and treatment outcomes. The growing prevalence of genetic disorders and chronic diseases, coupled with government funding for genomics research, is further boosting demand among hospitals and research institutions .
Saudi Arabia AI Genomics Market Competitive Landscape
The Saudi Arabia AI Genomics Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., QIAGEN N.V., Roche Sequencing Solutions, Agilent Technologies, Inc., PerkinElmer, Inc., Eurofins Scientific SE, Genomatix Software GmbH, 10x Genomics, Inc., Oxford Nanopore Technologies Ltd., Bio-Rad Laboratories, Inc., Ginkgo Bioworks, Inc., Myriad Genetics, Inc., Invitae Corporation, Sophia Genetics SA, Deep Genomics Inc., Fa
ic Genomics, Inc., Data4Cure, Inc., Saudi Human Genome Program (King Abdulaziz City for Science and Technology - KACST), King Faisal Specialist Hospital & Research Centre (Genomics and Precision Medicine Unit), Saudi Data and Artificial Intelligence Authority (SDAIA) contribute to innovation, geographic expansion, and service delivery in this space.
Illumina, Inc.
1998
San Diego, California, USA
Thermo Fisher Scientific Inc.
2006
Waltham, Massachusetts, USA
BGI Genomics Co., Ltd.
1999
Shenzhen, China
QIAGEN N.V.
1986
Venlo, Netherlands
Roche Sequencing Solutions
2006
Basel, Switzerland
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
Revenue Growth Rate (Saudi Arabia AI Genomics Segment)
Market Penetration Rate (Saudi Arabia)
Number of AI-Genomics Deployments/Projects in Saudi Arabia
R&D Investment as % of Revenue
Local Partnerships/Collaborations (Count/Key Names)
Saudi Arabia AI Genomics Market Industry Analysis
Growth Drivers
Increasing Investment in Healthcare Technology:
Saudi Arabia's healthcare expenditure is projected to reach approximately SAR 250 billion (USD 66.7 billion) in future, driven by a commitment to enhance healthcare infrastructure. The government aims to allocate 6% of its GDP to healthcare, fostering advancements in AI genomics. This investment supports the integration of cutting-edge technologies, enabling improved patient outcomes and personalized treatment options, thereby propelling the AI genomics market forward.
Rising Prevalence of Genetic Disorders:
The prevalence of genetic disorders in Saudi Arabia is estimated at 1 in 3 births, with conditions such as thalassemia and sickle cell disease being particularly common. This alarming statistic underscores the urgent need for genomic solutions. The increasing number of diagnosed cases is driving demand for genomic testing and personalized medicine, creating a robust market for AI-driven genomic technologies that can provide targeted therapies and preventive measures.
Government Initiatives for Digital Health:
The Saudi government has launched the "Vision 2030" initiative, which emphasizes digital health transformation. By future, the government plans to implement over 150 digital health projects, including genomic data integration into healthcare systems. This initiative aims to enhance healthcare delivery and accessibility, fostering an environment conducive to the growth of AI genomics, as it aligns with national health priorities and technological advancements.
Market Challenges
High Costs of Genomic Sequencing:
The cost of genomic sequencing in Saudi Arabia can exceed SAR 40,000 (USD 10,700) per individual, which poses a significant barrier to widespread adoption. This high expense limits access to genomic testing, particularly for lower-income populations. As a result, many patients may not receive timely diagnoses or personalized treatments, hindering the overall growth of the AI genomics market in the region.
Limited Awareness Among Healthcare Providers:
A significant gap exists in the awareness and understanding of genomic technologies among healthcare providers in Saudi Arabia. Only about 40% of healthcare professionals are familiar with the applications of AI in genomics. This lack of knowledge can lead to underutilization of genomic services, limiting patient access to innovative treatments and impeding the market's potential growth in the healthcare sector.
Saudi Arabia AI Genomics Market Future Outlook
The future of the AI genomics market in Saudi Arabia appears promising, driven by ongoing advancements in technology and increasing healthcare investments. As the government continues to prioritize digital health initiatives, the integration of AI in genomic data analysis is expected to enhance precision medicine. Furthermore, the rising demand for personalized healthcare solutions will likely stimulate innovation, leading to the development of new diagnostic tools and therapies that cater to the unique genetic profiles of the population.
Market Opportunities
Expansion of Personalized Medicine:
The growing emphasis on personalized medicine presents a significant opportunity for the AI genomics market. With an increasing number of patients seeking tailored treatment options, the demand for genomic testing and analysis is expected to rise, enabling healthcare providers to offer more effective and individualized therapies that improve patient outcomes.
Collaborations with International Research Institutions:
Partnerships with global research institutions can enhance the capabilities of Saudi Arabia's AI genomics market. By leveraging international expertise and resources, local companies can accelerate the development of innovative genomic solutions, fostering knowledge exchange and driving advancements in research and technology that benefit the healthcare sector.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
Table of Contents
88 Pages
- 1. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1. Increasing investment in healthcare technology
- 3.1.2. Rising prevalence of genetic disorders
- 3.1.3. Government initiatives for digital health
- 3.1.4. Advancements in AI and machine learning technologies
- 3.2. Restraints
- 3.2.1. High costs of genomic sequencing
- 3.2.2. Limited awareness among healthcare providers
- 3.2.3. Regulatory hurdles in data privacy
- 3.2.4. Shortage of skilled professionals in genomics
- 3.3. Opportunities
- 3.3.1. Expansion of personalized medicine
- 3.3.2. Collaborations with international research institutions
- 3.3.3. Development of AI-driven diagnostic tools
- 3.3.4. Growing demand for preventive healthcare solutions
- 3.4. Trends
- 3.4.1. Integration of AI in genomic data analysis
- 3.4.2. Increasing focus on precision medicine
- 3.4.3. Rise of telemedicine and remote diagnostics
- 3.4.4. Adoption of cloud-based genomic platforms
- 3.5. Government Regulation
- 3.5.1. Data protection laws for genomic data
- 3.5.2. Guidelines for ethical genomic research
- 3.5.3. Regulations on genetic testing services
- 3.5.4. Policies promoting AI in healthcare
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Segmentation, 2024
- 4.1. By Type (in Value %)
- 4.1.1. Whole Genome Sequencing
- 4.1.2. Exome Sequencing
- 4.1.3. Targeted Sequencing
- 4.1.4. RNA Sequencing
- 4.1.5. Others
- 4.2. By End-User (in Value %)
- 4.2.1. Hospitals
- 4.2.2. Research Institutions
- 4.2.3. Pharmaceutical & Biotechnology Companies
- 4.2.4. Diagnostic Laboratories
- 4.2.5. Others
- 4.3. By Application (in Value %)
- 4.3.1. Drug Discovery & Development
- 4.3.2. Precision Medicine
- 4.3.3. Disease Diagnosis
- 4.3.4. Genetic Research
- 4.4. By Distribution Channel (in Value %)
- 4.4.1. Direct Sales
- 4.4.2. Online Sales
- 4.4.3. Distributors
- 4.4.4. Others
- 4.5. By Investment Source (in Value %)
- 4.5.1. Government Funding
- 4.5.2. Private Investments
- 4.5.3. International Grants
- 4.5.4. Others
- 4.6. By Region (in Value %)
- 4.6.1. Central Region
- 4.6.2. Eastern Region
- 4.6.3. Western Region
- 4.6.4. Southern Region
- 4.6.5. Others
- 5. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1. Illumina, Inc.
- 5.1.2. Thermo Fisher Scientific Inc.
- 5.1.3. BGI Genomics Co., Ltd.
- 5.1.4. QIAGEN N.V.
- 5.1.5. Roche Sequencing Solutions
- 5.2. Cross Comparison Parameters
- 5.2.1. Revenue Growth Rate
- 5.2.2. Market Penetration Rate
- 5.2.3. Number of AI-Genomics Deployments/Projects in Saudi Arabia
- 5.2.4. R&D Investment as % of Revenue
- 5.2.5. Customer Segments Served
- 6. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Regulatory Framework
- 6.1. Compliance Requirements and Audits
- 6.2. Certification Processes
- 7. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. Saudi Arabia ai genomics Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Segmentation, 2030
- 8.1. By Type (in Value %)
- 8.2. By End-User (in Value %)
- 8.3. By Application (in Value %)
- 8.4. By Distribution Channel (in Value %)
- 8.5. By Investment Source (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
